Mesoblast Files 6-K, Updates ASX on February 15th Release
Ticker: MEOBF · Form: 6-K · Filed: Feb 21, 2024 · CIK: 1345099
| Field | Detail |
|---|---|
| Company | Mesoblast LTD (MEOBF) |
| Form Type | 6-K |
| Filed Date | Feb 21, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, foreign-issuer, biotechnology
TL;DR
**Mesoblast just dropped a 6-K, signaling new info from their Feb 15th ASX release is now public for US investors.**
AI Summary
Mesoblast Limited, an Australian biotechnology company, filed a 6-K report with the SEC on February 21, 2024, announcing a new release to the Australian Securities Exchange on February 15, 2024. This filing indicates that the company, identified by CIK 0001345099, is providing updated information to its investors, likely related to its biological products. The report was filed under the Securities Exchange Act of 1934, with a Commission File Number 001-37626.
Why It Matters
This filing signals Mesoblast is providing new information to the market, which could impact investor perception and stock performance.
Risk Assessment
Risk Level: low — The filing is a routine report of a foreign private issuer and does not inherently indicate a high level of risk.
Key Numbers
- 001-37626 — Commission File Number (Identifies Mesoblast's filing with the SEC)
- 0001345099 — Central Index Key (CIK) (Unique identifier for Mesoblast Limited)
Key Players & Entities
- Mesoblast Limited (company) — Registrant and filer of the 6-K
- Australian Securities Exchange (company) — Recipient of the original news release
- Silviu Itescu (person) — Chief Executive Officer and Executive Director of Mesoblast Limited
- February 15, 2024 (date) — Date of the original news release to ASX
- February 21, 2024 (date) — Date the 6-K was filed with the SEC
- 001-37626 (dollar_amount) — Commission File Number
FAQ
What is the purpose of Mesoblast Limited's 6-K filing?
Mesoblast Limited filed the 6-K to report a news release announcement made to the Australian Securities Exchange on February 15, 2024, making this information available to U.S. investors.
When was the original news release announced by Mesoblast Limited?
The original news release announcement was made on February 15, 2024, to the Australian Securities Exchange.
Who is the Chief Executive Officer and Executive Director of Mesoblast Limited?
Silviu Itescu is the Chief Executive Officer and Executive Director of Mesoblast Limited.
What is Mesoblast Limited's Commission File Number?
Mesoblast Limited's Commission File Number is 001-37626.
Where are Mesoblast Limited's principal executive offices located?
Mesoblast Limited's principal executive offices are located at Level 38, 55 Collins Street, Melbourne 3000, Australia.
Filing Stats: 213 words · 1 min read · ~1 pages · Grade level 17.3 · Accepted 2024-02-20 17:49:02
Filing Documents
- a2024-02x16fdagrantsorphan.htm (6-K) — 20KB
- exhibit991.htm (EX-99.1) — 13KB
- exhibit991001.jpg (GRAPHIC) — 276KB
- exhibit991002.jpg (GRAPHIC) — 308KB
- exhibit991003.jpg (GRAPHIC) — 193KB
- 0001345099-24-000017.txt ( ) — 1104KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly organized. Mesoblast Limited s Paul Hughes Paul Hughes Company Secretary Dated February 16, 2024 INDEX TO EXHIBITS Item 99.1 Press release of Mesoblast Ltd, dated February 15, 2024 .